Media ReleasesStirling Products Limited

View All Stirling Products Limited News


Collaboration Agreement to Accelerate ImmunoXel Introduction for TB Treatment

Agreement to Fast-Track New ImmunoXel Tablet Formulation

Healthcare group, Stirling Products Limited (ASX:STI) advises that the Company (Stirling) and its joint venture partner, Zodiac Capital Limited (Zodiac), have entered into a conditional agreement with Canadian based Immune Network Limited with regard to the Stirling exclusively licensed ImmunoXel product together with an improved formulation of ImmunoXel developed through recent work by Immune Network.

The new sublingual ImmunoXel tablet formulation has already demonstrated improved effectiveness and potential for accelerated cure rate. Importantly, the decreased cost of production, improved stability and ease of use of the new ImmunoXel formulation is likely to improve the accessibility and availability of the product for TB patients.

ImmunoXel (Dzherelo) is a multi-herbal extract that has been demonstrated in numerous clinical trials to be extraordinarily effective where provided as an adjunct in all forms of TB treatment, including the drug resistant forms MDR-TB and XDR-TB, as well as for patients with HIV/TB co-infection.


For further information please download PDF below:

Download this document